Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

PharmaVoice  |  June 18, 2024

“When you look at the list of 50-plus FDA approvals [in 2023], we know from pattern recognition that there’s going to be winners and losers, and some who have to work harder for it — we’ve seen increasing difficulty of achieving success,” said Leslie Orne. Read more from Leslie Orne, Trinity Life Sciences’ President and CEO, in PharmaVoice‘s latest article on ‘Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills.’